| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Crocin III targets oxidative stress pathways through its potent antioxidant activity. As a carotenoid glycoside, it scavenges free radicals and protects cells against oxidative damage. The compound exhibits neuroprotective effects, suggesting interactions with neuronal targets involved in neurodegeneration. Its anti-inflammatory activity indicates modulation of inflammatory signaling pathways. The compound's antidepressant effects suggest interactions with neurotransmitter systems involved in mood regulation. Crocin III's glycoside structure may influence its bioavailability and interactions with cellular targets. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Crocin III exhibits potent antioxidant activity through free radical scavenging. The compound shows neuroprotective effects in neuronal cell models, protecting against oxidative stress-induced cell damage. Its anti-inflammatory activity has been demonstrated in various cell-based systems by reducing pro-inflammatory cytokine production. The compound exhibits antidepressant-like effects in cell-based assays. As a crocetin glycoside, its stability and bioactivity have been characterized. These in vitro findings support its potential applications in oxidative stress research, neurodegenerative disease studies, and mood disorder research.
|
| ln Vivo |
In vivo studies have demonstrated that Crocin III exhibits neuroprotective effects in animal models of neurodegenerative diseases. Its antioxidant properties contribute to protection against oxidative damage in vivo. The compound shows antidepressant-like effects in behavioral animal models. Its anti-inflammatory activity has been observed in animal models of inflammation. As a major component of saffron, Crocin III contributes to the pharmacological effects of saffron extracts. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties and to evaluate its therapeutic potential in neurodegenerative and psychiatric disorders.
|
| Enzyme Assay |
In vitro enzyme and receptor binding assays for Crocin III typically involve testing its antioxidant activity using cell-free systems such as DPPH radical scavenging assays, ABTS assays, or ferric reducing antioxidant power (FRAP) assays. For anti-inflammatory activity, enzyme assays measuring COX, LOX, or other inflammatory enzymes are performed. Neuroprotective effects are assessed using assays measuring protection against oxidative stress-induced cell damage. Receptor binding studies may be performed to identify interactions with neurotransmitter receptors involved in mood regulation. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Crocin III involve culturing neuronal cells to evaluate its neuroprotective effects. Cells are treated with varying concentrations of the compound and then exposed to oxidative stress inducers such as H2O2 or glutamate. Cell viability is assessed using MTT or similar colorimetric assays. Reactive oxygen species levels are measured using fluorescent probes. For anti-inflammatory studies, immune cells are treated with the compound and stimulated with inflammatory stimuli; pro-inflammatory cytokine production is measured by ELISA. For antidepressant studies, neuronal cells are treated and neurotransmitter levels or signaling pathways are assessed. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Crocin III utilize rodent models to evaluate its neuroprotective, antidepressant, and anti-inflammatory activities. For neuroprotective studies, animals with induced neurodegeneration are treated with the compound and neurological function assessed. For antidepressant studies, animals are subjected to behavioral tests such as forced swim test or tail suspension test. For anti-inflammatory studies, animals with induced inflammation are treated and inflammatory markers measured. Parameters assessed include body weight, organ weights, behavioral scores, and histopathology. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Crocin III reflect its nature as a crocetin glycoside. It has a molecular weight and formula consistent with crocetin glycosides. As a water-soluble carotenoid, it is absorbed through the gastrointestinal tract. The compound is metabolized through standard pathways for glycosides, potentially releasing the aglycone crocetin. Its glycoside structure may affect its bioavailability. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
Crocin III is generally considered safe as a component of saffron, which has a long history of use as a food and medicinal spice. At research use concentrations, it is expected to have a favorable safety profile. However, as with all research chemicals, proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications. High doses of saffron extracts may have adverse effects.
|
| References |
|
| Additional Infomation |
β-D-Gentiobiosylcrocin is a dicarboxylic acid monoester formed by the condensation of a carboxylic acid group with the terminal hydroxyl group of β-D-gentiobiose. It is a dicarboxylic acid monoester, glycoside, and disaccharide derivative. Its function is related to crocin and gentiobiose. It is the conjugate acid of β-D-gentiobiosylcrocin (1-). It has been reported that β-D-gentiobiosylcrocin is found in gardenia (Gardenia jasminoides), saffron (Crocus sativus), and honeybees (Apis cerana), but the relevant data are still unclear.
Crocin III (CAS# 55750-85-1) is a crocetin glycoside and a major carotenoid component of saffron (Crocus sativus L.). It is one of the crocin series of compounds responsible for the characteristic color and pharmacological activities of saffron. Crocin III is a water-soluble carotenoid pigment with potent antioxidant properties. It exhibits neuroprotective, anti-inflammatory, and antidepressant activities. The compound is used in research applications for studying oxidative stress, neurodegenerative diseases, and mood disorders. Crocin III is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C32H44O14
|
|---|---|
| Molecular Weight |
652.68
|
| Exact Mass |
652.273
|
| CAS # |
55750-85-1
|
| PubChem CID |
10461942
|
| Appearance |
Light yellow to orange solid
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
46
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)O)O)O)OC(/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O)\C)\C)/C)/C)=O
|
| InChi Key |
VULLCGFNYWDRHL-YJOFKXFJSA-N
|
| InChi Code |
InChI=1S/C32H44O14/c1-17(11-7-13-19(3)29(40)41)9-5-6-10-18(2)12-8-14-20(4)30(42)46-32-28(39)26(37)24(35)22(45-32)16-43-31-27(38)25(36)23(34)21(15-33)44-31/h5-14,21-28,31-39H,15-16H2,1-4H3,(H,40,41)/b6-5+,11-7+,12-8+,17-9+,18-10+,19-13+,20-14+/t21-,22-,23-,24-,25+,26+,27-,28-,31-,32+/m1/s1
|
| Chemical Name |
(2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethyl-16-oxo-16-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexadeca-2,4,6,8,10,12,14-heptaenoic acid
|
| Synonyms |
crocin III
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5321 mL | 7.6607 mL | 15.3214 mL | |
| 5 mM | 0.3064 mL | 1.5321 mL | 3.0643 mL | |
| 10 mM | 0.1532 mL | 0.7661 mL | 1.5321 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
